BRIEF-Zymeworks Doses First Patient In Phase 1 Trial Of ZW191 For Folate Receptor-⍺ Positive Advanced Tumors

Reuters
05 Nov 2024

Nov 5 (Reuters) - Zymeworks Inc :

* ZYMEWORKS ANNOUNCES FIRST PATIENT DOSED IN PHASE 1 CLINICAL TRIAL EVALUATING ZW191 IN FOLATE RECEPTOR-⍺ EXPRESSING ADVANCED SOLID TUMORS

* ZYMEWORKS: EXPECTS TO ENROLL PATIENTS AT INVESTIGATOR SITES IN NORTH AMERICA, EUROPE, AND ASIA-PACIFIC REGION

Source text: Further company coverage:

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10